Search research articles
Contact Us
Filters
Showing results (1-10 of 159) with videos related to
Page
of 16
Sort By:
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
September 28, 2019
Biomarker Validation: Context and Complexities
Lisa M McShane
BMC Medicine
|
May 31, 2012
Statistical challenges in the development and evaluation of marker-based clinical tests
Lisa M McShane
JNCI Cancer Spectrum
|
July 31, 2019
Prospects for Minimal Residual Disease as a Surrogate Endpoint in Pediatric Acute Lymphoblastic Leukemia Clinical Trials
Lisa M McShane, Malcolm A Smith
Journal of Biopharmaceutical Statistics
|
August 26, 2016
Issues in developing multivariable molecular signatures for guiding clinical care decisions
Michael C Sachs, Lisa M McShane
Blood
|
December 17, 2016
Measure for measure: minimal residual disease in CLL
Richard F Little, Lisa M McShane
Journal of the National Cancer Institute
|
November 8, 2024
Evaluating clinical utility of comprehensive genomic profiling-challenges and opportunities
Lisa M McShane, Lyndsay N Harris
Statistics in Medicine
|
May 1, 2022
Sample size methods for evaluation of predictive biomarkers
Kevin K Dobbin, Lisa M McShane
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2012
Publication of tumor marker research results: the necessity for complete and transparent reporting
Lisa M McShane, Daniel F Hayes
Clinical Trials (London, England)
|
September 4, 2013
Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility
Lisa M McShane, Mei-Yin C Polley
Journal of Computational Biology : a Journal of Computational Molecular Cell Biology
|
August 7, 2002
A paradigm for class prediction using gene expression profiles
Michael D Radmacher, Lisa M McShane, Richard Simon
Page
of 16
Search research articles
Search
Showing results (1-10 of 159) with videos related to
Sort By:
Page
of 16
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
September 28, 2019
Biomarker Validation: Context and Complexities
Lisa M McShane
BMC Medicine
|
May 31, 2012
Statistical challenges in the development and evaluation of marker-based clinical tests
Lisa M McShane
JNCI Cancer Spectrum
|
July 31, 2019
Prospects for Minimal Residual Disease as a Surrogate Endpoint in Pediatric Acute Lymphoblastic Leukemia Clinical Trials
Lisa M McShane, Malcolm A Smith
Journal of Biopharmaceutical Statistics
|
August 26, 2016
Issues in developing multivariable molecular signatures for guiding clinical care decisions
Michael C Sachs, Lisa M McShane
Blood
|
December 17, 2016
Measure for measure: minimal residual disease in CLL
Richard F Little, Lisa M McShane
Journal of the National Cancer Institute
|
November 8, 2024
Evaluating clinical utility of comprehensive genomic profiling-challenges and opportunities
Lisa M McShane, Lyndsay N Harris
Statistics in Medicine
|
May 1, 2022
Sample size methods for evaluation of predictive biomarkers
Kevin K Dobbin, Lisa M McShane
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2012
Publication of tumor marker research results: the necessity for complete and transparent reporting
Lisa M McShane, Daniel F Hayes
Clinical Trials (London, England)
|
September 4, 2013
Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility
Lisa M McShane, Mei-Yin C Polley
Journal of Computational Biology : a Journal of Computational Molecular Cell Biology
|
August 7, 2002
A paradigm for class prediction using gene expression profiles
Michael D Radmacher, Lisa M McShane, Richard Simon
Page
of 16